NVIDIA and Eli Lilly announced a $1 billion collaboration to build an AI‑powered drug discovery laboratory in the San Francisco Bay Area. The pact combines NVIDIA’s computing and AI stack with Lilly’s drug‑development capabilities to run large‑scale computational biology and de‑risk early discovery work. Companies framed the partnership as a move from isolated pilots to an integrated discovery platform trained on proprietary datasets. The lab will host joint teams, bespoke models and high‑performance infrastructure to accelerate biologics and small‑molecule discovery. Lilly will both deploy the AI models on target discovery and supply data for model training; NVIDIA will provide hardware, software and engineering support. Executives said the aim is to reduce cycle times for lead identification and to create reusable AI models for multiple modalities.